跳至主要内容
临床试验/ChiCTR-TRC-14005054
ChiCTR-TRC-14005054进行中(未招募)4 期

抗凝血小板藥物『西洛他唑』用於抑制腦白質體病變之研究

General Research Fund1 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2014年9月1日最近更新:

试验速览

阶段
4 期
状态
进行中(未招募)
发起方
入组人数
140
试验地点
1
主要终点
Change of WMH volume on MRI between baseline and end of study, which will be quantified with automatic computational method

研究概览

简要总结

/

研究设计

研究类型
干预性研究
主要目的
随机平行对照
盲法
Double

入排标准

年龄范围
65 至 85(—)
性别
All

入选标准

  • Age 65-85;
  • Chinese ethnicity;
  • Presence of confluent on MRI*; and
  • Written informed consent given

排除标准

  • History of stroke or TIA;
  • Dementia according to Diagnostic and Statistical Manual of Mental Disorders, 4th edition;
  • Presence of peripheral arterial disease that necessitates use of cilostazol;
  • Concurrent use of antiplatelet agents or anticoagulants, e.g. aspirin, clopidogrel, warfarin;
  • Contraindications for use of cilostazol, e.g. heart failure, prior history of allergy to cilostazol;
  • Severe medical illnesses (e.g. malignancy, end-stage renal diseases);
  • Contraindication for MRI (e.g. claustrophobia, metallic implants).

研究组 & 干预措施

Two groups

Cilostazol/Placebov

结局指标

主要结局

Change of WMH volume on MRI between baseline and end of study, which will be quantified with automatic computational method

change in other brain measures in MRI (lacunes, microbleeds, brain volumes (cortical grey matter[cGM], white matter[WM], ventricular and sulcal CSF) and DTI measures (mean fractional anisotropy [FA] of WMH, normal appearing WM, GM) Clinical measures (Montreal Cognitive Assessment, 30-minute battery of the NINDS- CSN VCI Neuropsychology Protocols, NPI, instrumental activities of daily living, gait and balance , incident clinical events [e.g. stroke, dementia])

次要结局

未报告次要终点

研究者

发起方
General Research Fund

研究点 (1)

Loading locations...

相似试验